November 8, 2016 / 2:42 PM / 10 months ago

BRIEF-Valeant Pharmaceuticals sees lower 2017 revenue, adj EBITDA

Nov 8 (Reuters) - Valeant Pharmaceuticals International Inc executives, speaking on a conference call:

* Valeant Pharmaceuticals repaid $1.61 billion permanent debt year to date by Nov. 8; will pay $1.7 billion in 2016

* CFO expects 2017 revenue, adjusted EBITDA to be down from 2016

* CFO says company should keep core assets, but not at all cost

* CFO says company has addressed most 'unknowns' but could be more surprises ahead Further company coverage: (Reporting By Rod Nickel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below